

REMARKS

Applicants have amended the specification in two paragraphs in order to correct references in the text to certain figures. Applicants also submit herewith a complete set of replacement drawings. The objections set forth in the Notice to File Missing Parts dated January 20, 2004 with respect to Figures 20 and 32 have been corrected, and the drawing sheets have correctly numbered. In Figure 2, the designations of certain peptides have been corrected to P-6, P-4, P5-XB, and P12-XB, respectively. In Figure 14, the designations of certain peptides have been corrected to D2, D1, and D3, respectively. In Figure 22, the designation of the peptide has been corrected to D1. In Figure 23, the designation of the peptide has been corrected to D7. In Figure 24, the designation of the peptide has been corrected to D12-G. In Figure 32, the designations of certain peptides have been corrected to P30-XB, P31-XB, and p32-XB, respectively. In Figure 36, the designation of the peptide has been corrected to D6. In Figure 38, the designation of the peptide has been corrected to D23. Additionally, Figure 35 has been added. Figure 35 is the same as Figure 34 in the parent application U.S. Serial No. 10/379,287, which was incorporated by reference in its entirety into the subject application (see page 1, first paragraph). Because Figure 34 from the parent application has been properly incorporated by reference into the subject application, no new matter is introduced by the addition of Figure 35 into the replacement drawings (MPEP §201.06(c)).

No fee is deemed necessary in connection the filing of this amendment. If any fee is due, authorization is given to charge the amount of such fee to Deposit Account 50-0540.

Respectfully submitted,

Dated: March 22, 2004



Donald L. Rhoads, Reg. No. 34,705
W. Scott McNees, Reg. No. 33,964
KRAMER LEVIN NAFTALIS & FRANKEL LLP
919 Third Avenue
New York, New York 10022
(212) 715-9100 (telephone)
(212) 715-8000 (facsimile)